Estructura de I&D global: El caso Novartis

This article analyzes the organizational structure adopted by Novartis for the new product development effort. It has been identified that Novartis has different models of structure for different kinds of R&D activities (basic and clinical research). The clinical research is one of the more critical parts for the development of new pharmaceutical products. In Novartis, clinical research is accomplished in 42 countries, including Brazil, with a structure strongly commanded by the central administration. The operation is standardized by ptotocols that are followed by the investigators and guaranteed by the local departments of clinical research. This way, the coordination gets totally independent among countries and directly dependent of the central coordination of the clinical study. This study shows the advantages and disadvantages that are being obtained with the use this-model for the Brazilian case.